SM
AVNR

Sabby Management’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Sabby Management’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,750
Closed -$1.38M – 309
2014
Q1 		$1.38M Buy
3,750
+486
+15% +$1.85K 0.08% 125
2013
Q4 		$1.1M Buy
3,264
+730
+29% +$3.02K 0.07% 113
2013
Q3 		$1.07M Buy
+2,534
New +$12K 0.07% 119

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sabby Management's AVNR Position: Q3 2014 in Review

Sabby Management sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q3 2014, closing a stake of 434,000 shares — an estimated $2.96M sold.

Sabby Management first reported a position in AVNR in Q2 2013 and held it in 4 quarters. The position peaked at $2.45M in Q2 2014. 142 funds tracked by Wall St. Rank hold AVNR as of Q3 2014.

  • Sabby Management reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q3 2014 after selling out during the quarter.
  • Sabby Management sold 434,000 AVANIR PHARMACEUTICALS, INC CL A shares in Q3 2014, an estimated $2.96M.
  • Sabby Management first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 4 quarters.
  • Sabby Management's AVANIR PHARMACEUTICALS, INC CL A position peaked at $2.45M in Q2 2014.
  • 142 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q3 2014.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.